A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma
| Autor: | Dahish Ajarim, Shouki Bazarbashi, Amr El Weshi, Mohammed Memon, Adnan Ezzat, Chandrashekar Pai, Madras A. Raja, M. Rahal, Mohammed Al Fadda |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Esophageal Neoplasm Esophageal Neoplasms Injections Subcutaneous MEDLINE Adenocarcinoma Internal medicine Interferon α Drug Discovery Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans Pharmacology (medical) Infusions Intravenous Aged Pharmacology Cisplatin business.industry Pilot trial Interferon-alpha General Medicine Leukopenia Middle Aged medicine.disease Thrombocytopenia Clinical trial Infectious Diseases Treatment Outcome Fluorouracil Carcinoma Squamous Cell Female business medicine.drug |
| Zdroj: | Chemotherapy. 48(4) |
| ISSN: | 0009-3157 |
| Popis: | Background/Objectives: Based on the synergistic effect between cisplatin and 5-fluorouracil (5-FU), and between 5-FU and interferon-α, we conducted a trial to assess the response rate and toxicity of the combination of cisplatin, 5-FU and interferon-α in patients with advanced esophageal cancer. Methods: Patients with locally advanced or metastatic squamous cell or adenocarcinoma of the esophagus were eligible. No prior chemotherapy or interferon were allowed. Patients received cisplatin 80 mg/m2 on day 1, 5-FU 750 mg/m2/day by continuous intravenous infusion for 5 days, and interferon-α 5 × 106 units/m2/day by subcutaneous injection on days 1–5 of each cycle. Cycles were repeated every 21 days for a total of 6 cycles. Results: Forty patients were enrolled. Median age was 57.5 years (range 30–70). 33 had squamous carcinoma and 7 adenocarcinoma; 15 were male; the locoregional metastatic ratio was 1:39; median ECOG performance status was 2 (range 1–3). Grade 3–4 toxicities were: leukopenia (9 cases), thrombocytopenia (4), electrolyte imbalance (11), febrile neutropenia (11), vomitting (5), diarrhea (4), and mucositis (11). There were 3 early deaths, most probably related to therapy. Five patients (13%) achieved a complete response and 17 (42%) achieved a partial response, yielding an overall response rate of 55%. Response rates for squamous and adeno histology were 61% and 29%, respectively. Median survival was 6.4 months. Conclusion: The combination of cisplatin, 5-FU and interferon-α produces a high response rate in advanced squamous cell esophageal carcinoma, but with considerable toxicity. A modified combination of the above agents is presently being evaluated at our institution. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|